Article
The 4G/5G PAI-1 polymorphism influences the endothelial response to IL-1 and the modulatory effect of pravastatin.
Journal of thrombosis and haemostasis : JTH - 1 Aug 2006
Roncal C, Orbe J, Belzunce M, Rodríguez J A, Páramo J A
Abstract excerpt
BACKGROUND: Increased plasminogen activator inhibitor (PAI-1) levels lead to impaired fibrinolytic function associated with higher cardiovascular risk. PAI-1 expression may be regulated by different inflammatory cytokines such as interleukin-1alpha (IL-1). Several polymorphisms have been described in the PAI-1 gene. AIM: We examined the influence of the 4G/5G polymorphism in the promoter region on...
Topics
- Analysis of Variance
- Atherosclerosis
- Cells, Cultured
- Endothelium, Vascular
- Enzyme-Linked Immunosorbent Assay
- Genotype
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Interleukin-1
- Plasminogen Activator Inhibitor 1
- Polymorphism, Genetic
- Pravastatin
- Promoter Regions, Genetic
- Umbilical Veins